Hunan Province Tumor Hospital clinical trial pipeline

10 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 10 with minor changes only.

1. Minor

   10 trials marked Unknown by the registry's verification sweep

   1. Minor

      Intrathecal Pemetrexed Combined With High-dose Furmonertinib and…Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

      Hunan Province Tumor Hospital·Phase 2· NCT06537297· Registry history of NCT06537297 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   2. Minor

      Intrathecal Pemetrexed for SCLC · Refractory Brain Metastases or…Intrathecal Pemetrexed for SCLC · Refractory Brain Metastases or Leptomeninges Metastatic

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

      Hunan Province Tumor Hospital·Phase 2· NCT06497543· Registry history of NCT06497543 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   3. Minor

      High-dose Furmonertinib for First-line Treatment of EGFR Mutated…High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Phase 2· NCT05379803· Registry history of NCT05379803 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   4. Minor

      Atezolizumab Combined With Platinum-based Chemotherapy as…Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy · Resectable Stage II-IIIB

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Phase 2· NCT05295212· Registry history of NCT05295212 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   5. Minor

      JS-201 Combined With Lenvatinib · Small-cell Lung Cancer

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Phase 2· NCT04951947· Registry history of NCT04951947 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   6. Minor

      Real-World Study of Treatment Patterns and Effectiveness in MET…Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Not specified· NCT06183762· Registry history of NCT06183762 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   7. Minor

      Compassionate Use Study of NHWD-870 · Advanced Solid Tumors or…Compassionate Use Study of NHWD-870 · Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Not specified· NCT06073938· Registry history of NCT06073938 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   8. Minor

      Central Nervous System Metastatic EGFR Mutation Positive…Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Not specified· NCT05991193· Registry history of NCT05991193 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   9. Minor

      Chemotherapy Combined With Immunotherapy in HER 2 Insertion or…Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hunan Province Tumor Hospital·Not specified· NCT04324125· Registry history of NCT04324125 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   10. Minor

       Pembrolizumab Combined With Double Platinum Based Chemotherapy for…Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

       Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

       Hunan Province Tumor Hospital·Not specified· NCT04324151· Registry history of NCT04324151 on ClinicalTrials.gov (opens the registry)

       Changed Oct 4, 2026

   Registry verification sweep

   Changed Oct 4, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.